Faron Pharmaceuticals Awarded €3.8 Million Award in Arbitration Case

Faron Pharmaceuticals (LON: FARN) announced Tuesday that it has won its arbitration case against Rentschler Biopharma SE.

The arbitration tribunal appointed by the Arbitration Institute of the Stockholm Chamber of Commerce (SCC) ruled in favor of Faron.

Also Read: The Best Healthcare Stocks to Buy

The clinical-stage biopharmaceutical company was awarded €3.8 million after seeking damages from Rentschler for the unfounded termination of an agreement concerning the manufacturing process for Faron’s drug Traumakine.

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

“As previously communicated, a third-party recovery services provider funded the proceedings for Faron. The funder will receive compensation from Faron in accordance with the litigation funding agreement,” the company said. 

Should you invest in Faron Pharmaceuticals shares?

Faron Pharmaceuticals shares are traded on the London stock exchange’s AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Faron Pharmaceuticals shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies